Selexis’ biologic platform generates first-ever approved Soliris biosimilar 11-Apr-2019 By Maggie Lynch First-ever Soliris biosimilar approved in Russia after it was produced through Selexis’ SureTechnology platform and cell line.
Berkeley Lights looks to CAR-T manufacture after securing $95m investment 19-Oct-2018 By Ben Hargreaves This week Berkeley announced it had tied up a financing round and signed a cell line development deal with Selexis.
NEWS IN BRIEF Selexis and Symphogen expand partnership to progress two mAbs 11-Jul-2018 By Ben Hargreaves Selexis and Symphogen have announced that the latter has submitted INDs for clinical programmes to progress two mAbs using Selexis’ platform.